09:47 AM EDT, 05/14/2025 (MT Newswires) -- ATyr Pharma ( ATYR ) said Wednesday it has advanced ATYR0101 to the investigational new drug candidate stage to potentially treat pulmonary fibrosis.

Chief Executive Sanjay S. Shukla said they anticipate filing an IND application in H2 of 2026.

The company said preclinical data showed ATYR0101 can induce cell death of myofibroblasts through interaction with LTBP-1. Myofibroblasts are the cells that drive progression of fibrosis.

Shares of the company were down 1.2% in early trading Wednesday.

Price: 3.27, Change: -0.04, Percent Change: -1.21